The Cancer Letter

Inside information on cancer research and drug development

In Brief

Ovarian Cancer National Alliance and Ovarian Cancer Research Fund merge

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE OVARIAN CANCER NATIONAL ALLIANCE and the OVARIAN CANCER RESEARCH FUND announced a merger, forming the Ovarian Cancer Research Fund Alliance. The new body will be the largest global organization dedicated to advancing ovarian cancer research.

“The Ovarian Cancer Research Fund Alliance believes we can gain more ground together, fighting disease through a ‘one-stop shop’ approach to research, advocacy, education and awareness,” said OCRFA President and CEO Audra Moran. “The formation of OCRFA will propel ovarian cancer prevention and treatment forward at an accelerated pace.”

Between the two organizations, nearly $70 million has been invested over the past 22 years in research grants to diagnose, treat and cure ovarian cancer.

“This merger will unite the ovarian cancer community under one strong voice. OCRFA is committed to continuing and expanding the many patient-centered programs begun by both the Ovarian Cancer National Alliance and Ovarian Cancer Research Fund in the past, including, the Ovarian Cancer National Conference, Survivors Teaching Students and Woman to Woman,” said OCRFA Executive Vice President Calaneet Balas.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
By W. Kimryn Rathmell
Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account